Korro Bio, Inc. (KRRO): Cash & Equivalents
$21.82M
As of 2025-12-31
$24.91M
As of 2026-06-30
-15.6%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $21.82M | -60.8% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $55.64M | -66.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $166.15M | +357.3% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $36.33M | n/c | 2024-03-26, Balance as of period end |
| 2021-12-31 | $79.64M | -63.9% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $220.34M | +10.1% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $200.16M | +374.4% | 2021-03-29, Balance as of period end |
| 2018-12-31 | $42.19M | n/a | 2020-03-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $21.82M | -60.8% |
| Immunome Inc. (IMNM) | 2025-12-31 | $653.48M | +355.9% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $199.16M | +39.6% |
| Adagene Inc. (ADAG) | 2025-12-31 | $74.52M | -12.5% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
Compare KRRO, IMNM, WHWK, OVID side by side · Screen every company in Pharmaceutical Preparations ↗